The phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) as a first-line treatment for people with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer showed positive results.
Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.
